Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data

Christopher Kim, Sumita Bhatta, Lori Cyprien, Rafael Fonseca, Rohini K. Hernandez

Research output: Contribution to journalArticle

4 Scopus citations


Skeletal-related events (SREs) are common bone complications in multiple myeloma (MM). However, there are few real-world reports of their incidence. In this study, a database of oncology electronic health records was linked to administrative claims data. Patients identified were aged ≥18 years and newly diagnosed with MM, had ≥1 clinic visit within 1 month of diagnosis, and ≥1 year of follow-up after diagnosis. The study period was January 1, 2011 to December 31, 2016. 343 patients were included, 35% of whom had a baseline history of any SRE. During a median follow-up of 25.7 months, 34% of patients experienced SREs after diagnosis. Median time to SRE was 167 days. Among patients experiencing an SRE, 68% had an SRE within the first year. The incidence rate of SREs at 1 year following MM diagnosis for patients with baseline history was 103/100 person-years (PY) versus 16/100PY for patients without baseline history. SRE incidence rates within 3 months of initiating a line of therapy increased with subsequent lines (line 1: 81/100PY, line 2: 118/100PY, line 3: 150/100PY). Risk of SREs was similar across different anti-MM regimens, including proteasome inhibitor-based regimens. These results highlight the importance of continued surveillance and management of MM-associated bone disease.

Original languageEnglish (US)
Article number100215
JournalJournal of Bone Oncology
StatePublished - Feb 1 2019



  • Bone disease
  • Multiple myeloma
  • Proteasome inhibitor
  • Skeletal-related event

ASJC Scopus subject areas

  • Oncology

Cite this